Evidence map›Paper›PMID 26261062›Full record

ArticleThe pharmacogenomics journal2016

Attitudes of clinicians following large-scale pharmacogenomics implementation.

J F Peterson, J R Field, Y Shi, J S Schildcrout, J C Denny, T L McGregor, S L Van Driest, J M Pulley, I M Lubin, M Laposata and 2 more

Abstract read
In one paragraph

Article in The pharmacogenomics journal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Toward Integration of Pharmacogenomic Tests into Daily Clinical Practice: A General Survey for Polish Healthcare Workers.Medical science monitor : international medical journal of experimental and clinical research · 2023
    Article
  6. How to Implement a Pharmacogenetics Service at your Institution.Journal of the American College of Clinical Pharmacy : JACCP · 2022
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Improved provider preparedness through an 8-part genetics and genomic education program.Genetics in medicine : official journal of the American College of Medical Genetics · 2022
    Article
  12. Genophenotypic Factors and Pharmacogenomics in Adverse Drug Reactions.International journal of molecular sciences · 2021
    Review
  13. Approaches to assessing the provider experience with clinical pharmacogenomic information: a scoping review.Genetics in medicine : official journal of the American College of Medical Genetics · 2021
    Article
  14. The Role of Electronic Health Records in Advancing Genomic Medicine.Annual review of genomics and human genetics · 2021
    Review
  15. A Practical Utility and Benefit of Pharmacogenetic-based Antidepressant Treatment Strategy for Major Depressive Disorder Patients with Difficult-to-treat.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2021
    Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

J F PetersonDepartment of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN, USA.
J R FieldVanderbilt Institute for Clinical and Translational Research, Nashville, TN, USA.
Y ShiDepartment of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA.
J S SchildcroutDepartment of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA.
J C DennyDepartment of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN, USA.
T L McGregorDepartment of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, USA.
S L Van DriestDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
J M PulleyVanderbilt Institute for Clinical and Translational Research, Nashville, TN, USA.
I M LubinCenters for Disease Control and Prevention, Atlanta, GA, USA.
M LaposataUniversity of Texas Medical Branch, Galveston, TX, USA.
D M RodenDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
E W ClaytonDepartment of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, USA.

Funding

The Vanderbilt Institute for Clinical and Translational Research (VICTR)UL1TR000445 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BERNARD, GORDON RAPHAEL · 2012 to 2016
$41.4M
Pharmacogenomics of Arrhythmia TherapyU19HL065962 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RODEN, DAN M · 2010 to 2014
$17.4M
Pharmacogenomics of Anti-platlet Intervention-2 (PAPI-2) StudyU01HL105198 · NHLBI · UNIVERSITY OF MARYLAND BALTIMORE · PI SHULDINER, ALAN R. · 2010 to 2014
$13.6M
VGER, the Vanderbilt Genome-Electronic Records ProjectU01HG008672 · NHGRI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI DENNY, JOSHUA C., RODEN, DAN M · 2015 to 2019
$5.1M
Integrated, Individualized, Intelligent Prescribing (I3P)U01HG007253 · NHGRI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI LEVY, MIA A., PETERSON, JOSEPH F. · 2014 to 2018
$4.6M
Vanderbilt Genome Electronic Records ProjectU01HG006378 · NHGRI · VANDERBILT UNIVERSITY · PI RODEN, DAN M · 2011 to 2014
$4.0M
The Vanderbilt Institute for Clinical and Translational Research (VICTR)KL2TR000446 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BERNARD, GORDON RAPHAEL · 2012 to 2016
$2.8M
Rational Integration of Genomic Healthcare Testing (RIGHT)U01HL122904 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI GRAVES, JOHN A., PETERSON, JOSEPH F. · 2013 to 2016
$1.9M
PHARMACOGENOMIC RESOURCE FOR ENHANCED DECISIONS IN CLOPIDOGREL TREATMENT (PREDICTU47CI000824 · CI · VANDERBILT UNIVERSITY · PI LAPOSATA, MICHAEL · 2011 to 2012
$998k
MTRNR1 Aminoglycoside Ototoxicity Outcomes and Parental Perceptions of TestingK23HD000001 · NICHD · VANDERBILT UNIVERSITY · PI MCGREGOR, TRACY L. · 2012 to 2014
$528k
NCATS NIH HHS KL2 TR000446NCATS NIH HHS UL1 TR000445NCPDCID CDC HHS U47 CI000824NHGRI NIH HHS U01 HG006378NHGRI NIH HHS U01 HG007253NHGRI NIH HHS U01 HG008672NHLBI NIH HHS U01 HL105198NHLBI NIH HHS U01 HL122904NHLBI NIH HHS U19 HL065962NICHD NIH HHS K23 HD000001
6 · The paper itself

Abstract

Clinician attitudes toward multiplexed genomic testing may be vital to the success of translational programs. We surveyed clinicians at an academic medical center about their views on a large pharmacogenomics implementation, the PREDICT (Pharmacogenomic Resource for Enhanced Decisions in Care and Treatment) program. Participants were asked about test ordering, major factors influencing use of results, expectations of efficacy and responsibility for applying results to patient care. Virtually all respondents (99%) agreed that pharmacogenomics variants influence patients' response to drug therapy. The majority (92%) favored immediate, active notification when a clinically significant drug-genome interaction was present. However, clinicians were divided on which providers were responsible for acting on a result when a prescription change was indicated and whether patients should be directly notified of a significant result. We concluded genotype results were valued for tailoring prescriptions, but clinicians do not agree on how to appropriately assign clinical responsibility for actionable results from a multiplexed panel.The Pharmacogenomics Journal advance online publication, 11 August 2015; doi:10.1038/tpj.2015.57.

Indexed as

Attitude of Health PersonnelHealth Knowledge, Attitudes, PracticePharmacogeneticsAdultAgedDrug-Related Side Effects and Adverse ReactionsFemaleGenotypeHumansMaleMiddle AgedPerceptionPharmacogenomic TestingPharmacogenomic VariantsPhenotypePhysicians

Identifiers

PMID26261062
PMCPMC4751074

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.